-
Your selected country is
United Kingdom
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
CD45RA FITC
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
The antibody reagent is stable until the expiration date shown on the label when stored at 2°C to 8°C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry.
Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration.
CD45RA is intended for in vitro diagnostic use in the identification of cells expressing CD45RA antigen, using a BD FACS™ brand flow cytometer. The flow cytometer must be equipped to detect light scatter and the appropriate fluorescence, and be equipped with appropriate analysis software (such as BD CellQuest™ or BD LYSYS™ II software) for data acquisition and analysis. Refer to your instrument user’s guide for instructions.
Development References (14)
-
Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in healthcare settings. MMWR. 1988; 37:377-388. (Biology).
-
Clinical Applications of Flow Cytometry: Quality Assurance and Immunophenotyping of Lymphocytes: Approved Guideline. NCCLS document H42-A. 1998. (Biology).
-
Cobbold SP, Hale G, Waldmann H. Non-lineage, LFA-1 family, and leucocyte common antigens: new and previously defined clusters. In: McMichael AJ. A.J. McMichael .. et al., ed. Leucocyte typing III : white cell differentiation antigens. Oxford New York: Oxford University Press; 1987:788-803.
-
Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Rothe G, Schmitz G. Leukemia. 1996; 10:877-895. (Biology).
-
Isoda A, Yokohama A, Matsushima R, Tsukamoto N, Nojima Y, Karasa M. The naive T-lymphocyte compartment is well preserved in patients with chronic myelogenous leukaemia in chronic phase. Br J Haematol. 2002; 119:949-955. (Biology).
-
Jackson AL, Warner NL. Rose NR, Friedman H, Fahey JL, ed. Manual of Clincial Laboratory Immunology, Third Edition. Washington DC: American Society for Microbiology; 1986:226-235.
-
Mackus WJ, Frakking FN, Grummels A, et al. Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia.. Blood. 2003; 102(3):1057-63. (Biology). View Reference
-
Morimoto C, Letvin NL, Distaso JA, Aldrich WR, Schlossman SF. The isolation and characterization of the human suppressor/inducer T-cell subset. J Immunol. 1985; 134:1508-1515. (Biology).
-
NCCLS document. 2001. (Biology).
-
Rose LM, Ginsberg AH, Rothstein TL, Ledbetter JA, Clark EA. Selective loss of a subset of T helper cells in active multiple sclerosis.. Proc Natl Acad Sci USA. 1985; 82(21):7389-93. (Biology). View Reference
-
Serra HM, Krowka JF, Ledbetter JA, Pilarski LM. Loss of CD45R (Lp220) represents a post-thymic T cell differentiation event.. J Immunol. 1988; 140(5):1435-41. (Biology). View Reference
-
Sobel RA, Hafler DA, Castro EE, Morimoto C, Weiner HL. The 2H4 (CD45R) antigen is selectively decreased in multiple sclerosis lesions.. J Immunol. 1988; 140(7):2210-4. (Biology). View Reference
-
Stelzer GT, Marti G, Hurley A, McCoy PJ, Lovett EJ, Schwartz A. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997; 30:214-230. (Biology).
-
Trimoreau F, Donnard M, Turlure P, Gachard N, Bordessoule D, Feuillard J. The CD4+ CD56+ CD116– CD123+ CD45RA+ CD45RO– profile specific of DC2 malignancies. Haematologica. 2003; 88:ELT10. (Biology).
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For In Vitro Diagnostic Use.
23-22942-00
Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.